Pyrimethamine is exclusively used in combination with a sulfonamide (sulfadiazine, sulfadoxine) or a sulfone

Comments · 339 Views

The global pyrimethamine market is estimated to be valued at US$ 1,106.8 million in 2022 and expected to increase to US$ 1,655.1 Mn by 2030, witnessing a CAGR of 5.2% over the forecast period (2022-2030).

Pyrimethamine, a dihydrofolate reductase inhibitor, is the current standard of care for AIDS-related TE. The use of pyrimethamine with sulfadiazine or pyrimethamine plus clindamycin is normal procedure.

During the acute phase of treatment for TE, prospective, randomised trials found that pyrimethamine plus clindamycin and pyrimethamine plus sulfadiazine were equally effective. 14,106,107 A panel of experts recommends taking 600 mg of clindamycin orally (or intravenously) every 6 hours when adopting a clindamycin-containing regimen.

 

Explore Complete Blog- https://bit.ly/3NptnI0

Comments